Published in Oncology Business Week, July 26th, 2009
"The results show that MDTFC could efficiently and selectively inhibit the proliferation of several human cancer cell lines. Among all the cell lines, THP-1 was found to be most sensitive (IC50 29.59 mc M), whereas the peripheral blood mononuclear cells were least effected (IC50 464.16 mc M). The molecular...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.